Multiple Endocrine Neoplasia Type 2b D018814

Related MeSH Hierarchy (5)

Diseases [C] » Endocrine System Diseases [C19] » Endocrine Gland Neoplasms » Multiple Endocrine Neoplasia » Multiple Endocrine Neoplasia Type 2b

Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Endocrine Gland Neoplasms » Multiple Endocrine Neoplasia » Multiple Endocrine Neoplasia Type 2b

Diseases [C] » Neoplasms [C04] » Neoplasms, Multiple Primary » Multiple Endocrine Neoplasia » Multiple Endocrine Neoplasia Type 2b

Diseases [C] » Neoplasms [C04] » Neoplastic Syndromes, Hereditary » Multiple Endocrine Neoplasia » Multiple Endocrine Neoplasia Type 2b

Diseases [C] » Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] » Genetic Diseases, Inborn » Neoplastic Syndromes, Hereditary » Multiple Endocrine Neoplasia » Multiple Endocrine Neoplasia Type 2b

Description

Similar to MEN2A, it is also caused by mutations of the MEN2 gene, also known as the RET proto-oncogene. Its clinical symptoms include medullary carcinoma (CARCINOMA, MEDULLARY) of THYROID GLAND and PHEOCHROMOCYTOMA of ADRENAL MEDULLA (50%). Unlike MEN2a, MEN2b does not involve PARATHYROID NEOPLASMS. It can be distinguished from MEN2A by its neural abnormalities such as mucosal NEUROMAS on EYELIDS; LIP; and TONGUE, and ganglioneuromatosis of GASTROINTESTINAL TRACT leading to MEGACOLON. It is an autosomal dominant inherited disease.   MeSH

Hierarchy View

View MeSH Tree View ICD-10 Tree

Phase 2 Indicated Drugs (1)

sorafenib (nexavar)

Phase 1 Indicated Drugs (3)

capecitabine (xeloda)

temozolomide (temodar)

veliparib


Organization Involved with Phase 2 Indications (2)

National Cancer Institute (NCI)

Ohio State University

Organization Involved with Phase 1 Indications (1)

Vanderbilt University

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.